Rapport Therapeutics Inc. (RAPP)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rapport Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ML Marc Larkins Johnson & Johnson | 1.78M | $41.51M | $72.02M | $30.52M | 73.52% |
| BG Bart Gancher Intech Investment Management LLC | 7,035 | $213,441.9 | $282,379.27 | $68,937.37 | 32.3% |
 John H. Burbank III Passport Capital LLC | 1.55M | $35.87M | $62.1M | $26.23M | 73.14% |
 Joseph Castro Nuveen LLC | 71,508 | $1.73M | $2.88M | $1.15M | 66.72% |
| TC Thomas Cagna Sandia Investment Management LP | 6,000 | $178,200 | $241,978.2 | $63,778.2 | 35.79% |
Rapport Therapeutics Inc. (RAPP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rapport Therapeutics Inc. ever had a stock split?
Rapport Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Abraham N. Ceesay CEO | NASDAQ (NMS) Exchange | 75383L102 CUSIP |
| US Country | 84 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Rapport Therapeutics, Inc. is a progressive clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule medicines aimed at treating patients with central nervous system (CNS) disorders. Established in 2022 and based in Boston, Massachusetts, the company leverages its expertise in neuroscience to target a range of debilitating conditions, focusing on creating therapies that address significant unmet medical needs.
Products and Services
- RAP-219
This is Rapport Therapeutics' leading product candidate, representing a pioneering approach in the treatment of focal epilepsy and other CNS disorders such as peripheral neuropathic pain and bipolar disorder. RAP-219 is an investigational small molecule crafted to inhibit TARPy8-containing AMPARs with remarkable picomolar affinity. The therapeutic aim of RAP-219 demonstrates Rapport Therapeutics' focused commitment to pushing the boundaries of CNS disorder treatment.
- RAP-199
A successor to RAP-219, RAP-199 stands out due to its targeted approach towards TARPy8 and distinctive chemical and pharmacokinetic properties. This compound underlines the company's ongoing efforts in expanding its portfolio with innovative molecules designed to target CNS disorders with high precision.
- Nicotinic Acetylcholine Receptor (nAChR) Programs
Rapport Therapeutics also advances its mission through the development of specific nicotinic acetylcholine receptor programs, notably:
- a6 nAChR: Targeted to treat chronic pain, this program aims to explore the therapeutic potential of nAChR subtypes in managing pain without the drawbacks of traditional pain management therapies.
- a9a10 nAChR: Geared towards the treatment of hearing disorders, this innovative approach reflects the company's dedication to addressing less common but equally challenging CNS disorders through targeted receptor modulation.
